Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TRDA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ENTR-601-44 | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 · NCT07037862 | Recruiting |
| ENTR-601-45 | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 · NCT07038824 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TRDA holds $193M in cash and short-term investments (as of Sep 30, 2026) and burns about $31.2M/quarter from operations, an estimated runway of 18.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 48 · Elevated
We have identified conditions that raise substantial doubt about our ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRDA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP 10% owner |
Insider | 4,691,392 | 11.98% | 2025-11-20 |
| MPM BIOVENTURES 2018, L.P. 10% owner |
Insider | 3,885,115 | 9.92% | 2026-09-04 |
| MPM BioVentures 2014, L.P. 10% owner Includes shares also reported by MPM BIOVENTURES 2018, L.P., counted once |
Insider | 3,885,115 | 9.92% | 2026-09-04 |
| ANSBERT GADICKE | 5%+ holder (13D) | 3,885,115 | 9.92% | 2026-09-08 |
| 5AM Ventures V, L.P. 10% owner |
Insider | 3,877,094 | 9.90% | 2026-08-06 |
| Kush Parmar Director · +19,000 options |
Insider | 3,784,650 | 9.67% | 2026-08-06 |
| Dipal Doshi CEO, Director · +208,000 options |
Insider | 517,290 | 1.32% | 2026-09-02 |
| Natarajan Sethuraman President, Research & Develop. · +83,200 options |
Insider | 214,238 | 0.55% | 2026-09-02 |
| Nathan J Dowden President & COO · +133,031 options |
Insider | 196,060 | 0.50% | 2026-09-02 |
| Kory James Wentworth Chief Financial Officer · +66,600 options |
Insider | 117,277 | 0.30% | 2026-09-02 |
| Bernhardt G Zeiher Director · +19,000 options |
Insider | 5,000 | 0.01% | 2026-05-20 |
Share count 39,150,334 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRDA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →